Ulcerative colitis in children and adolescents from the western region of saudi arabia

Saudi Medical Journal

Volumn 32, Issue 9, 2011, Pages 943-947

  Saadah, Omar I ^a  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; MESALAZINE;

ABDOMINAL PAIN; ADOLESCENT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; ENDOSCOPY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPOALBUMINEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PEDIATRICIAN; RECTUM HEMORRHAGE; RELAPSE; RETROSPECTIVE STUDY; SAUDI ARABIA; TENESMUS; THROMBOCYTOSIS; ULCERATIVE COLITIS; VOMITING; WEIGHT REDUCTION; AGE; GASTROINTESTINAL HEMORRHAGE; INCIDENCE; PATHOLOGY; RECTUM;

ADOLESCENT; AGE FACTORS; CHILD; COLITIS, ULCERATIVE; DIARRHEA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; RECTUM; RETROSPECTIVE STUDIES; SAUDI ARABIA;

EID: 84856368986     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000; 14: 1553-1559.
2. Loftus EV, Jr., Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000; 46: 336-343.
3. Kirsner JB, Shorter RG. Recent developments in nonspecific inflammatory bowel disease (second of two parts). N Engl J Med 1982; 306: 837-848.
4. Alamin AH, Ayoola EA, El Boshra AS, Hamaza MK, Gupta V, Ahmed MA. Ulcerative colitis in Saudi Arabia: a retrospective analysis of 33 cases treated in a regional referral hospital in Gizan. Saudi J Gastroenterol 2001; 7: 55-58.
5. Contractor QQ, Contractor TQ, Ul Haque I, El Mahdi el Mel B. Ulcerative colitis: Al-Gassim experience. Saudi J Gastroenterol 2004; 10: 22-27.
6. El Mouzan MI, Al Quorain A, Ul-Haque A. Ulcerative colitis in Saudi children. Ann Saudi Med 1989; 9: 612-614.
7. El Mouzan MI, Abdullah AM, Al Habbal MT. Epidemiology of juvenile-onset inflammatory bowel disease in central Saudi Arabia. J Trop Pediatr 2006; 52: 69-71.
8. de Silva HJ, de Silva NR, de Silva AP, Jewell DP. Emergence of inflammatory bowel disease 'beyond the West': do prosperity and improved hygiene have a role? Trans R Soc Trop Med Hyg 2008; 102: 857-860.
9. Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006; 21: 1772-1782.
10. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753.
11. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
12. Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006; 4: 1118-1123.
13. Grossman BJ, DeBenedetti CD. Extraintestinal manifestations of chronic inflammatory bowel disease in children. Proc Inst Med Chic 1970; 28: 119.
14. Stawarski A, Iwanczak B, Krzesiek E, Iwanczak F. [Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease]. Pol Merkur Lekarski 2006; 20: 22-25.
15. Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 63-68.
16. El-Mouzan MI, Al-Salloum AA, Al-Herbish AS, Qurachi MM, Al-Omar AA. Regional variations in the prevalence of consanguinity in Saudi Arabia. Saudi Med J 2007; 28: 1881-1884.
17. Roma ES, Panayiotou J, Pachoula J, Constantinidou C, Polyzos A, Zellos A, et al. Inflammatory bowel disease in children: the role of a positive family history. Eur J Gastroenterol Hepatol 2010; 22: 710-715.
18. Lee JH, Cheon JH, Moon CM, Park JJ, Hong SP, Kim TI, et al. Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older? Digestion 2010; 81: 237-243.
19. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006; 12: 543-550.
20. Henriksen M, Jahnsen J, Lygren I, Sauar J, Schulz T, Stray N, et al. Change of diagnosis during the first five years after onset of inflammatory bowel disease: results of a prospective follow-up study (the IBSEN Study). Scand J Gastroenterol 2006; 41: 1037-1043.
21. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005; 146: 35-40.
22. Lichtenstein GR. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm Bowel Dis 2001; 7: 89-93.
23. Worledge KL, Godiska R, Barrett TA, Kink JA. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci 2000; 45: 2298-22305.
24. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 19-37.
25. Rossetti S, Actis GC, Fadda M, Rizzetto M, Palmo A. The use of the anti-tumour necrosis factor monoclonal antibody-infliximab--to treat ulcerative colitis: implications and trends beyond the available data. Dig Liver Dis 2004; 36: 426-431.
26. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787.
27. Russell RK, Wilson ML, Loganathan S, Bourke B, Kiparissi F, Mahdi G, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 946-953.
28. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-110.
29. Kabakchiev B, Turner D, Hyams J, Mack D, Leleiko N, Crandall W, et al. Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis. PLoS One 2010; 5: e13085.